The sales of antiinfective medicines in Norway are projected to experience steady growth from 2024 to 2028. In 2023, the sales stood at 285.6 million USD PPP. Year-on-year growth rates are forecasted to be approximately 3.06% in 2024, 3.06% in 2025, 2.97% in 2026, 2.85% in 2027, and 2.76% in 2028. The compound annual growth rate (CAGR) for the period from 2024 to 2028 is anticipated to be around 2.94%.

The following trends should be closely monitored:

Innovations in antimicrobial resistance (AMR) management that could alter market dynamics and sales.
Regulatory changes and healthcare policies impacting antiinfective medicine use and pricing.
Potential economic fluctuations influencing healthcare budgets and expenditures.
Emergence of new infectious diseases creating spikes in demand for antiinfective treatments.